Abbott Laboratories $ABT Stock Holdings Lifted by iA Global Asset Management Inc.

iA Global Asset Management Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 94.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 144,062 shares of the healthcare product maker’s stock after buying an additional 69,803 shares during the period. iA Global Asset Management Inc.’s holdings in Abbott Laboratories were worth $19,296,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. IMG Wealth Management Inc. lifted its holdings in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the last quarter. Anfield Capital Management LLC increased its position in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the period. Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories in the second quarter valued at $32,000. Curio Wealth LLC boosted its holdings in shares of Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after acquiring an additional 305 shares during the period. Finally, Pineridge Advisors LLC grew its position in shares of Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock worth $43,000 after acquiring an additional 81 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Mizuho boosted their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a report on Thursday, October 16th. Raymond James Financial boosted their price target on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Finally, Wells Fargo & Company raised their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $147.39.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $108.50 on Friday. Abbott Laboratories has a 1 year low of $105.78 and a 1 year high of $141.23. The firm has a market cap of $188.67 billion, a P/E ratio of 13.60, a PEG ratio of 2.00 and a beta of 0.72. The stock has a fifty day moving average price of $125.23 and a two-hundred day moving average price of $128.54. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 31.58%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech / devices strength helped offset weakness elsewhere — management said Devices/MedTech delivered solid growth in Q4, cushioning the hit from Nutrition and Diagnostics. Read More.
• Positive Sentiment: Adjusted EPS and margins improved — adjusted EPS grew ~12% and matched street expectations, with margin gains driven by product mix and cost improvements. This supports the company’s cash generation and capital-return capacity. Read More.
• Neutral Sentiment: Reported EPS met consensus ($1.50), limiting the severity of the selloff from an earnings-surprise perspective. Read More.
• Negative Sentiment: Revenue missed expectations — Q4 revenue was below consensus ($~11.5B vs. ~$11.8B est), driven by a contraction in Nutrition (~‑9%) and weakness in Diagnostics (lower COVID testing and aid-related volatility). That top‑line miss is the main catalyst for the decline. Read More.
• Negative Sentiment: Guidance came in slightly below street models — Q1 EPS guide (1.120–1.180) and FY 2026 adjusted EPS (5.550–5.800) skated under consensus, which amplified selling pressure given the revenue shortfall. Read More.
• Negative Sentiment: Unusual bearish options activity — traders bought a large volume of puts (reported ~80,600), signaling elevated short‑term hedging or directional bearish bets that can accelerate downward moves in the stock.
• Negative Sentiment: Market reaction and media coverage — widespread headlines on the revenue miss and weaker outlook pushed the shares lower and into fresh downside territory, with analysts noting the pullback even as most maintain constructive long‑term views. Read More.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.